Latest news with #TMA
Yahoo
2 hours ago
- Business
- Yahoo
Tixel i® Demonstrates Sustained Improvements in Dry Eye Symptoms
Recent Publication Reports Durable Results and Patient Satisfaction KNOXVILLE, Tenn., June 3, 2025 /PRNewswire/ -- A new article in JOJ Ophthalmology confirms Tixel i® provides sustained, strong clinical outcomes for patients with Evaporative Dry Eye Disease (DED) caused by Meibomian Gland Dysfunction (MGD). This FDA-cleared, non-invasive device uses patented Thermo-Mechanical Action® (TMA®) to deliver durable improvements in key indicators, including patient satisfaction and clinical results. Key Highlights Tear Break-Up Time (TBUT): Improved significantly from 4.0 ± 1.5 seconds to 9.2 ± 4.0 seconds, reaching a normal physiological range. Meibomian Gland Score (MGS): Increased by over 17 points, comparable to or exceeding thermal pulsation systems. Ocular Surface Disease Index (OSDI): Scores dropped by over 21 points, reflecting reduced symptoms and significantly improved quality of life. Safety: No device-related adverse effects were recorded. Real World Experience Confirms Study Results One 76-year-old patient with severe dry eye, unable to tolerate traditional treatments like IPL, found significant relief with Tixel i. Dr. Lauren Bailey of West Plano Dry Eye and Aesthetics noted, "It's quick, easy, and finally gave us a way forward after hitting so many walls. Tixel i is perfect for our low vision patients." Dr. Bailey also treated a 53-year-old patient with a two-year history of severe dry eye that required eye drops four to six times daily. Following a treatment plan that included three sessions of Tixel i, the patient reported noticeable improvement in discomfort and a substantial reduction in the impact of dry eye on daily activities. By the four-week follow-up, her clinical severity had improved from severe to moderate, drop usage had decreased, and objective metrics showed dramatic improvement: TBUT increased from 0 to 8 seconds and MGSS improved from 2 to 40 (OD) and 39 (OS), leading to reduced eye drop usage and improved daily activities. For more information, fill out this form: About Novoxel® Established in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit Novoxel, Tixel, and Thermo-Mechanical Action (TMA) are registered trademarks of Novoxel Ltd. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Business
- Yahoo
Leading New York Ophthalmologist Integrates Tixel® into Dry Eye Treatments
WATERTOWN, N.Y., June 3, 2025 /PRNewswire/ -- Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and revenue growth after adding Tixel i into his practice. Tixel i, Novoxel's FDA-cleared device, utilizes patented Thermo-Mechanical Action® (TMA) to effectively treat Meibomian Gland Dysfunction (MGD) – a common cause of dry eye – in under two minutes. Within just two months, Dr. Sanni's team treated over 225 patients, making Tixel i a truly transformative addition to their dry eye protocols. Dr. Sanni noted, "We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance." CLINICALLY PROVEN RESULTS - Tixel i isn't just praised by patients; it's backed by strong clinical data. A pivotal trial showed remarkable improvements: Tear Break-Up Time (TBUT) improved from severe to normal physiological range and sustained for 6 months. Meibomian Gland Score (MGS) increased by over 17 points, comparable to or exceeding thermal pulsation systems. Ocular Surface Disease Index (OSDI) scores dropped by more than 21 points, indicating a significant improvement in patients' quality of life. Crucially, no adverse device-related effects were reported. PHYSICIAN ENDORSEMENT - Dr. Debra Koloms, Medical Director at Center for Sight New York, personally experienced Tixel i treatment for her own dry eye. "After 2 Tixel i treatments, I no longer need punctal plugs or drops," she shared. After personally treating over 50 patients in six weeks, Dr. Koloms declared, "In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction." Center for Sight New York offers consultations and Tixel i treatment previews for those interested in learning more about this innovative dry eye solution. Novoxel, Tixel, Thermo-Mechanical Action, and TMA are registered trademarks of Novoxel LTD. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit ABOUT CENTER FOR SIGHTEstablished in the 1940s, Center for Sight New York is one of Northern New York's largest and most respected eye care practices, with locations in Watertown and Ogdensburg. Under the leadership of Dr. Noaman Sanni since 1995, the practice boasts a team of board-certified ophthalmologists and skilled technicians. They provide state-of-the-art diagnostics and advanced treatments with a patient-centered approach, aiming to improve quality of life through exceptional vision solutions. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Automotive
- Yahoo
Driver runs from scene after crashing into construction equipment on I-70; 1 flown to hospital
One person was flown to the hospital after a crash on I-70 in Clark County early Monday. [DOWNLOAD: Free WHIO-TV News app for alerts as news breaks] As reported on News Center 7 Daybreak, Ohio State Highway Patrol troopers and medics responded just before 1:45 a.m. to Interstate 70 near State Route 4 on reports of a crash. TRENDING STORIES: 18-year-old dead, 1 injured in Champaign County crash Body found in trunk of burning car in Dayton; homicide investigation launched Police looking for man suspected of stealing over $1,300 worth of items from Kroger An investigation found that a driver of a Subaru Legacy was eastbound on I-70 and hit a truck-mounted attenuator (TMA). TMAs are energy-absorbing devices attached to the rear of trailers or trucks. After hitting the TMA, the Subaru was disabled in the roadway, and the driver ran from the scene, according to the Ohio State Highway Patrol. A Hyundai Elantra hit the disabled Subaru. The operator of the TMA and the 28-year-old driver of the Hyundai were not hurt in the crash. The 36-year-old passenger in the Hyundai was flown to Miami Valley Hospital. An ODOT spokesperson confirmed the crash involved an ODOT contractor. He said 66 ODOT crews have been hit in 2025. They had 88 ODOT crews hit in 2024. We will continue to follow this story. [SIGN UP: WHIO-TV Daily Headlines Newsletter]
Yahoo
4 days ago
- General
- Yahoo
Local physician named President-Elect of Texas Medical Association
CENTRAL TEXAS (FOX 44) – A Central Texas physician is on his way to becoming the 161st president of the Texas Medical Association (TMA). The TMA has elected Bradford W. Holland, MD, as its new president-elect, placing the Central Texas-based otolaryngologist on course to become the association's 161st president in May 2026. The TMA says the election took place during TexMed, TMA's annual conference, held this year in San Antonio. Dr. Holland is the first TMA president elected from Waco in more than five decades. Dr. Holland practices at Coryell Health in Gatesville and Waco. He says his goal as TMA president-elect is to preserve the medical profession for future generations, a mission that originally inspired his involvement in advocacy. He also encourages physicians to engage in policy efforts which safeguard the physician-patient relationship and strengthen the future of medicine. The TMA says Dr. Holland has been a member for more than 30 years, starting as a medical student at UT Southwestern. He is a graduate of the TMA Leadership College, served on the Council on Legislation, and was first elected vice speaker of the TMA House of Delegates in 2019. Dr. Holland led the House through the COVID-19 pandemic, later serving four terms as speaker. He also chaired TEXPAC, TMA's political action committee. In addition to his TMA leadership, Dr. Holland is a past president of both the McLennan County Medical Society and the Texas Association of Otolaryngology. He is board-certified by the American Board of Otolaryngology, and serves as adjunct faculty in Baylor University's Department of Communication Sciences and Disorders. The TMA says Dr. Holland and his wife, Amanda Holland, director of advising for Baylor's Robbins College of Health and Human Sciences, live in Waco and have four children. The couple enjoys attending concerts, serving in community arts leadership, and fly fishing in mountain trout streams. Dr. Holland will serve a one-year term as president-elect before officially assuming the role of TMA president in May 2026. The TMA is the largest state medical society in the nation, and represents more than 59,000 physician and medical student members. It is dedicated to improving the health of all Texans. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 days ago
- Business
- Yahoo
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection. Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company's main value driver as the key reason for the downgrade.'We continue to have a favorable view of RP-A501's efficacy; however, we see increased uncertainty for the product given safety concerns,' Blum said in an analyst note. Blum anticipates limited readthrough to Rocket's other AAV programs, which utilize simpler immunosuppression regimens. Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while maintaining the Buy rating. While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note. Livshits reduced the probability of success from 70% to 40%, given CBER leadership's focus on benefit/risk, pending more details regarding agency feedback and next steps. The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers. Chardan notes the company hasn't revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment. Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation. Chardan highlights that it's still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There's no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays. Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe. Other analyst reactions: Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5. Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8. Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19. Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday. Read Next:Image via Shutterstock Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Dec 2021 Chardan Capital Maintains Buy Aug 2021 SVB Leerink Maintains Outperform View More Analyst Ratings for RCKT View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
